

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version  
9.1

Revision Date:  
13.11.2025

SDS Number:  
20433-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

### SECTION 1. IDENTIFICATION

Product identifier : Raltegravir Pediatric Granules Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : Avenida Tanner de Melo, Quadra 10 Lote 4A, Galpão A  
Parque Industrial Vice Presidente José Alencar Aparecida de  
Goiás – GO, Brazil

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS Classification of the substance or mixture in accordance with ABNT NBR 14725 Standard

Serious eye damage : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity - single exposure : Category 3

Short-term (acute) aquatic hazard : Category 3

#### GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H318 Causes serious eye damage.  
H335 May cause respiratory irritation.  
H361d Suspected of damaging the unborn child.  
H402 Harmful to aquatic life.

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version 9.1 Revision Date: 13.11.2025 SDS Number: 20433-00027 Date of last issue: 09.05.2025 Date of first issue: 09.10.2014

### Precautionary Statements

#### : Prevention:

P201 Obtain special instructions before use.  
P261 Avoid breathing dust.  
P271 Use only outdoors or in a well-ventilated area.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

#### : Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.  
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

#### : Storage:

P405 Store locked up.

### Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Raltegravir	871038-72-1	Acute Tox. (Oral), 5 Eye Dam., 1 Repr., 2 STOT SE, 3 Aquatic Acute, 3	>= 20 - < 25
Cellulose	9004-34-6		>= 20 - < 30
Magnesium stearate	557-04-0		>= 1 - < 5
Ammonium hydroxide	1336-21-6	Acute Tox. (Oral), 4 Skin Corr., 1B Eye Dam., 1 Aquatic Acute, 1 Aquatic Chronic, 2	>= 0,1 - < 0,25

## SECTION 4. FIRST AID MEASURES

### Description of necessary first-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version 9.1	Revision Date: 13.11.2025	SDS Number: 20433-00027	Date of last issue: 09.05.2025 Date of first issue: 09.10.2014
----------------	------------------------------	----------------------------	---

	When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Causes serious eye damage. May cause respiratory irritation. Suspected of damaging the unborn child. Contact with dust can cause mechanical irritation or drying of the skin.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

### Indication of any immediate medical attention and special treatment needed

Notes to physician	: Treat symptomatically and supportively.
--------------------	---

## SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO <sub>x</sub> ) Fluorine compounds Metal oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version 9.1	Revision Date: 13.11.2025	SDS Number: 20433-00027	Date of last issue: 09.05.2025 Date of first issue: 09.10.2014
----------------	------------------------------	----------------------------	---

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Surround spill with absorbents and place a damp covering over the area to minimize entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Avoid breathing dust. Do not swallow. Do not get in eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version 9.1	Revision Date: 13.11.2025	SDS Number: 20433-00027	Date of last issue: 09.05.2025 Date of first issue: 09.10.2014
----------------	------------------------------	----------------------------	---

	<p>respiratory irritants or sensitizers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.</p>
Hygiene measures	<p>: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.</p>
Conditions for safe storage	<p>: Keep in properly labeled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.</p>
Materials to avoid	<p>: Do not store with the following product types: Strong oxidizing agents</p>

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Raltegravir	871038-72-1	TWA	1000 (µg/m <sup>3</sup> ) (OEB 1)	Internal
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH
Ammonium hydroxide	1336-21-6	TWA	25 ppm (Ammonia)	ACGIH
		STEL	35 ppm (Ammonia)	ACGIH

Engineering measures	<p>: Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.</p>
----------------------	--

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version 9.1      Revision Date: 13.11.2025      SDS Number: 20433-00027      Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

### Personal protective equipment

Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type
Hand protection	
Material	: Chemical-resistant gloves
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	: powder
Color	: off-white
Odor	: odorless
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: No data available
Relative vapor density	: No data available
Relative density	: No data available
Solubility(ies)	

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version 9.1 Revision Date: 13.11.2025 SDS Number: 20433-00027 Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

Water solubility	: No data available
Partition coefficient: n-octanol/water	: No data available
Autoignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle characteristics	
Particle size	: No data available

---

## SECTION 10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

---

## SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	: Inhalation Skin contact Ingestion Eye contact
--	--

### Acute toxicity

Not classified based on available information.

### Product:

Acute oral toxicity	: Acute toxicity estimate: > 5.000 mg/kg Method: Calculation method
---------------------	--

### Components:

#### Raltegravir:

Acute oral toxicity	: LD50 (Mouse, male and female): > 2.000 mg/kg
---------------------	--

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version 9.1      Revision Date: 13.11.2025      SDS Number: 20433-00027      Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

### **Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

### **Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials  
Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg  
Remarks: Based on data from similar materials

### **Ammonium hydroxide:**

Acute oral toxicity : LD50 (Rat): 350 mg/kg  
Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

### **Skin corrosion/irritation**

Not classified based on available information.

### **Components:**

#### **Raltegravir:**

Species : Rabbit  
Result : No skin irritation

#### **Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

#### **Ammonium hydroxide:**

Species : Rabbit  
Result : Corrosive after 3 minutes to 1 hour of exposure  
Remarks : Based on national or regional regulation.

### **Serious eye damage/eye irritation**

Causes serious eye damage.

### **Components:**

#### **Raltegravir:**

Species : Bovine cornea

**Raltegravir Pediatric Granules Formulation**

Version 9.1	Revision Date: 13.11.2025	SDS Number: 20433-00027	Date of last issue: 09.05.2025 Date of first issue: 09.10.2014
----------------	------------------------------	----------------------------	---

Result : Severe irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

**Ammonium hydroxide:**

Result : Irreversible effects on the eye  
Remarks : Based on skin corrosivity.

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Raltegravir:**

Test Type : Local lymph node assay (LLNA)  
Species : Mouse  
Result : negative

**Magnesium stearate:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Raltegravir:**

Genotoxicity in vitro : Test Type: reverse mutation assay  
Result: negative

Test Type: Alkaline elution assay  
Test system: rat hepatocytes  
Result: negative

Test Type: Chromosomal aberration  
Method: OECD Test Guideline 473  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Mouse

**Raltegravir Pediatric Granules Formulation**Version  
9.1Revision Date:  
13.11.2025SDS Number:  
20433-00027Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

Result: negative

Test Type: Chromosomal aberration

Method: OECD Test Guideline 475

Result: negative

**Cellulose:**

Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Result: negativeTest Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo

: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative**Magnesium stearate:**

Genotoxicity in vitro

: Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materialsTest Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Remarks: Based on data from similar materials

**Ammonium hydroxide:**

Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative**Carcinogenicity**

Not classified based on available information.

**Components:****Raltegravir:**

Species

: Mouse, male and female

Exposure time

: 104 weeks

Result

: negative

**Cellulose:**

Species

: Rat

Application Route

: Ingestion

Exposure time

: 72 weeks

Result

: negative

**Raltegravir Pediatric Granules Formulation**Version  
9.1Revision Date:  
13.11.2025SDS Number:  
20433-00027Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:****Raltegravir:**

Effects on fertility

: Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Application Route: Oral  
General Toxicity Parent: NOAEL: 600 mg/kg body weight  
Result: negative

Effects on fetal development

: Species: Rat  
Application Route: Oral  
General Toxicity Maternal: NOAEL:  $\geq$  600 mg/kg body weight  
Teratogenicity: LOAEL F1: 300 mg/kg body weight  
Symptoms: Skeletal malformations.  
Result: positive

Species: Rabbit  
General Toxicity Maternal: NOAEL:  $\geq$  1.000 mg/kg body weight  
Teratogenicity: NOAEL:  $\geq$  1.000 mg/kg body weight  
Result: negative

Reproductive toxicity - Assessment

: Some evidence of adverse effects on development, based on animal experiments.

**Cellulose:**

Effects on fertility

: Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development

: Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Magnesium stearate:**

Effects on fertility

: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on fetal development

: Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version  
9.1

Revision Date:  
13.11.2025

SDS Number:  
20433-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

Remarks: Based on data from similar materials

### STOT-single exposure

May cause respiratory irritation.

#### Components:

##### **Raltegravir:**

Routes of exposure : Inhalation  
Target Organs : Respiratory Tract  
Assessment : May cause respiratory irritation.

### STOT-repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### Components:

##### **Raltegravir:**

Species : Dog  
NOAEL : 90 mg/kg  
Application Route : Oral  
Exposure time : 371 d  
Symptoms : Vomiting

Species : Rat  
NOAEL : 30 mg/kg  
LOAEL : 120 mg/kg  
Application Route : Oral  
Exposure time : 189 d  
Target Organs : Stomach

Species : Mouse  
NOAEL : 50 mg/kg  
LOAEL : 500 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Target Organs : Stomach

Species : Rat  
NOAEL : 50 mg/kg  
LOAEL : 200 mg/kg  
Application Route : Oral  
Exposure time : 8 Weeks  
Target Organs : Stomach

##### **Cellulose:**

Species : Rat  
NOAEL : >= 9.000 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Raltegravir Pediatric Granules Formulation**

Version 9.1 Revision Date: 13.11.2025 SDS Number: 20433-00027 Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

**Magnesium stearate:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Raltegravir:**

Ingestion : Symptoms: Nausea, Diarrhea, Headache, Fever, Rash, Skin irritation

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Raltegravir:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 66 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3,8 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 9,3 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 9,5 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

## SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 09.05.2025  
9.1 13.11.2025 20433-00027 Date of first issue: 09.10.2014

Toxicity to microorganisms : EC50: > 1.000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 1.000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

## Cellulose:

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)) : > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

## **Magnesium stearate:**

Toxicity to fish : LC50 (*Leuciscus idus* (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

NOELR (*Pseudokirchneriella subcapitata* (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

### Ammonium hydroxide:

Toxicity to fish : LC50 (*Oncorhynchus mykiss* (rainbow trout)): 0,89 mg/l  
Exposure time: 96 h  
Test substance: Neutralized product

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version 9.1 Revision Date: 13.11.2025 SDS Number: 20433-00027 Date of last issue: 09.05.2025 Date of first issue: 09.10.2014

---

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 101 mg/l Exposure time: 48 h
M-Factor (Acute aquatic toxicity)	:	1
Toxicity to fish (Chronic toxicity)	:	NOEC (Oncorhynchus mykiss (rainbow trout)): 0,0135 mg/l Exposure time: 73 d Test substance: Neutralized product
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0,961 mg/l Exposure time: 21 d Remarks: Based on data from similar materials

### Persistence and degradability

#### Components:

##### **Raltegravir:**

Biodegradability	:	Result: rapidly degradable Biodegradation: 50 % Exposure time: 9 d Method: OECD Test Guideline 302B
Stability in water	:	Hydrolysis: < 10 %(5 d) Method: OECD Test Guideline 111

##### **Cellulose:**

Biodegradability	:	Result: Readily biodegradable.
------------------	---	--------------------------------

##### **Magnesium stearate:**

Biodegradability	:	Result: Not biodegradable Remarks: Based on data from similar materials
------------------	---	--

### Bioaccumulative potential

#### Components:

##### **Raltegravir:**

Partition coefficient: n-octanol/water	:	log Pow: -0,328
--	---	-----------------

##### **Magnesium stearate:**

Partition coefficient: n-octanol/water	:	log Pow: > 4
--	---	--------------

### **Mobility in soil**

No data available

### **Other adverse effects**

No data available

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

---

Version 9.1	Revision Date: 13.11.2025	SDS Number: 20433-00027	Date of last issue: 09.05.2025 Date of first issue: 09.10.2014
----------------	------------------------------	----------------------------	---

---

### SECTION 13. DISPOSAL CONSIDERATIONS

#### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

### SECTION 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

Not regulated as a dangerous good

##### IATA-DGR

Not regulated as a dangerous good

##### IMDG-Code

Not regulated as a dangerous good

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### Domestic regulation

##### ANTT

Not regulated as a dangerous good

#### Special precautions for user

Not applicable

---

### SECTION 15. REGULATORY INFORMATION

#### Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - : Not applicable  
(LINACH)

Brazil. List of chemicals controlled by the Federal Police : Not applicable

#### The ingredients of this product are reported in the following inventories:

AICS : not determined

CA. DSL : not determined

IECSC : not determined

---

### SECTION 16. OTHER INFORMATION

Revision Date : 13.11.2025

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version 9.1	Revision Date: 13.11.2025	SDS Number: 20433-00027	Date of last issue: 09.05.2025 Date of first issue: 09.10.2014
----------------	------------------------------	----------------------------	---

Date format : dd.mm.yyyy

### Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

ACGIH / STEL : Short-term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

# SAFETY DATA SHEET



## Raltegravir Pediatric Granules Formulation

Version  
9.1

Revision Date:  
13.11.2025

SDS Number:  
20433-00027

Date of last issue: 09.05.2025  
Date of first issue: 09.10.2014

---

BR / Z8